Topics

Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn

07:55 EDT 11 Oct 2019 | Pharmaceutical Business Review

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced

The post Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn appeared first on Pharmaceutical Business review.

Original Article: Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn

NEXT ARTICLE

More From BioPortfolio on "Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...